^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    CancerSCAN

    Company:
    Geninus
    Type:
    Laboratory Developed Test
    Details
    Evidence

    News

    3ms
    Identification and validation of novel prognostic genetic markers in HER2-negative advanced gastric cancer (AGC) by artificial intelligence (AI) deep learning and machine learning algorithm (AACR 2024)
    This study showed the potential of AI deep learning and machine learning pipeline that employs an innovate prognostic genetic markers for HER2-negative AGC. Current ongoing analyses of larger cohort with more comprehensive clinical data will be presented.
    PARP Biomarker • BRCA Biomarker • Machine learning • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CREBBP (CREB binding protein) • FANCA (FA Complementation Group A) • IL7R (Interleukin 7 Receptor) • FAT3 (FAT Atypical Cadherin 3) • NOTCH4 (Notch 4) • BARD1 (BRCA1 Associated RING Domain 1) • BCL2A1 (BCL2 Related Protein A1) • FANCM (FA Complementation Group M) • ZNF217 (Zinc Finger Protein 217) • HLPP2 (PH Domain And Leucine Rich Repeat Protein Phosphatase 2)
    |
    HER-2 negative
    |
    CancerSCAN
    4ms
    Identification Of Tumor-Specific Genes In Cervix Sample Of Ovarian Cancer Patients (ESGO 2024)
    Cervix samples might be a non-invasive diagnostic method for ovarian cancer. Further research and validation are warranted to confirm these findings.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    CancerSCAN
    9ms
    Next-generation Sequencing in Breast Cancer Patients: Real-world Data for Precision Medicine. (PubMed, Cancer Res Treat)
    NGS can provide information about predictive biomarkers and drug-targetable biomarkers that can enable treatment and participation in clinical trials based on precision medicine. Further studies should be conducted to excavate novel drug-targetable biomarkers and develop additional target therapies.
    Real-world evidence • Journal • BRCA Biomarker • Next-generation sequencing • Real-world
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    TP53 mutation • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • HR positive + HER-2 negative
    |
    TruSight Oncology 500 Assay • CancerSCAN
    11ms
    Clinical Validation of the Unparalleled Sensitivity of the Novel ADPS Technology-Based EGFR Mutation Assay in Patients with Operable Non-Small Cell Lung Cancer. (PubMed, Cancer Res Treat)
    "Based on the EGFR genotyping by ADPS, the treatment options could be switched in five patients. The highly sensitive and specific ADPS™ EGFR Mutation Test Kit would be useful in detecting the patients who have lung cancer with EGFR mutation, and can benefit from the EGFR targeted therapy."
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation
    |
    cobas® EGFR Mutation Test v2 • ADPS™ EGFR Mutation Test Kit • CancerSCAN